1. Scrip
  2. >>Business
  3. >>Manufacturing

Pharma Calls On UK Govt To Fund Centers of Excellence

 
• By Kevin Grogan

The Medicines Manufacturing Industry Partnership says £140m invested in four centers would provide high-skilled jobs and make the UK the first place in the world where drugs can be discovered, made and packaged.

Pill capsule with Great Britain flag. UK health care concept, 3D rendering
Flying the flag: UK playing catch-up on manufacturing medicines • Source: Shutterstock

The UK pharmaceutical sector is asking the government to dip into its coffers and invest some £140m into creating four new centers of excellence for medicines manufacturing across the country.

A report, Manufacturing Vision for UK Pharma, has been published today by the Medicines Manufacturing Industry Partnership (MMIP) which asks...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

OneSource CEO On Next-Gen GLP-1 Innovator Talks, Xbrane And Viatris Partnering

 
• By Vibha Ravi

OneSource Specialty CEO Neeraj Sharma discusses with Scrip exploratory talks with next-gen GLP-1 innovators, prospects for semaglutide generics and investment in Swedish firm Xbrane, among other topics.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By Jung Won Shin

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

More from Business

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.

Finance Watch: BeOne Raises $885m In Imdelltra Royalty Sale

 
• By Mandy Jackson

BeOne could realize up to $950m under a deal with Royalty Pharma for its portion of sales from Amgen’s DLL3 inhibitor. Also, Novavax refinanced convertible debt, Kriya Therapeutics raised $313.3m in venture capital and Vaxxas garnered A$89.2m ($57.9m) in venture debt and cash.